WednesdayMay 29, 2024 9:00 am

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) CEO Featured as Guest in Recent Bell2Bell Podcast

CEO explains that Aston Bay is in the business of adding value through discovery of high-grade critical metals and precious metals deposits ATBHF is working with partner to develop the Storm Copper Project, located in Canada Storm project is serving as a model as the company looks to discover, develop other projects Aston Bay Holdings (TSX.V: BAY) (OTCQB: ATBHF) CEO Thomas Ullrich talked all things copper in a recent episode of the Bell2Bell podcast, which delivers informative updates and exclusive interviews with executives operating in fast-moving industries (https://ibn.fm/fwJak). During the interview, Ullrich and host Stuart Smith discussed key information about…

Continue Reading

TuesdayMay 28, 2024 12:00 pm

Social Media Strategies Summit For Senior Level Marketing Professionals:  Presenting The Most Efficient and Relevant Marketing Strategies

The Social Media Strategies Summit invites senior-level marketing professionals, executives, and enthusiasts, for a series of meaningful discussions, networking, and learning sessions, being held on June 12-13, 2024, as a virtual conference. In addition to the general summit, SMSsummit has lined up two exclusive workshops to enhance your experience. On June 11, 2024, dive deep into the world of digital strategy with two optional workshops crafted for keen learners. Kickstart your day with the first workshop, “Brand Messaging, Content Creation, and Data-Informed Social Strategies,” where you'll unlock the secrets to crafting compelling content and leveraging data for impactful social media…

Continue Reading

TuesdayMay 28, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024

Lexaria, a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2 GLP-1, a class of drugs, has demonstrated the ability to address diabetes and weight loss, albeit with poor oral bioavailability, usually as little as 0.8% Lexaria, through its study, looks to demonstrate the effectiveness of its DehydraTECH(TM) technology in improving GLP-1’s bioavailability, opening up a vast worldwide market Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2 (https://ibn.fm/74Pee). This follows the recent…

Continue Reading

TuesdayMay 28, 2024 9:45 am

Growing EM Applications as America Adopts Ankle Monitors for Asylum Seekers

SuperCom, a global leading provider of traditional and digital identity solutions, is tapping into the growing use cases for electronic monitoring (“EM”) solutions globally New adoption of the technology is seen in a move by the U.S. government to use ankle monitors to also track asylum seekers entering the country to help support and expedite their asylum process For SuperCom, this is a further validation of the value of EM solutions, their versatility and overall effectiveness SuperCom’s management anticipates a growth in the demand for its products as the conversation around these solutions continues to proliferate SuperCom (NASDAQ: SPCB), a…

Continue Reading

TuesdayMay 28, 2024 9:00 am

Tartisan Nickel Corp. (CSE: TN) (OTCQB: TTSRF) (FSE: 8TA) Grows Asset Portfolio with Additional Claims Acquisition at the Flagship Kenbridge Nickel Project

Tartisan Nickel Corp., a Canadian mineral and battery materials exploration and mining development company, just acquired additional contiguous claims at its flagship Kenbridge Nickel Project This brings the total coverage to 4,273 ha, with 93 contiguous patents, four mining licenses, and 153 single-cell mining claims The company also announced the commencement of the 2024 baseline field work conducted by Aspen Biological Ltd. These two milestones are a testament to the company’s commitment to creating shareholder value and following through with its plans for the 2024 calendar year Tartisan Nickel (CSE: TN) (OTCQB: TTSRF) (FSE: 8TA), a Canadian mineral and battery…

Continue Reading

FridayMay 24, 2024 10:30 am

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF), JV Partner Report New Exploration Targets at Storm Project Amid Rising Copper Prices

Preliminary interpretation of initial MLEM survey results indicates new exploration targets highlighting excellent potential to discover additional copper mineralization Copper process projected to continue upward trend Results open “a whole new space for potential discovery,” says Aston Bay CEO As copper prices climb to a 2024 high, Aston Bay Holdings (TSX.V: BAY) (OTCQB: ATBHF) is reporting initial results from geophysical activities that are currently underway at its Nunavut-based Storm Copper Project (https://ibn.fm/d5faa). According to the report, preliminary interpretation of the initial moving loop electromagnetic (“MLEM”) survey results indicates several new exploration targets highlighting excellent potential to discover additional copper mineralization.…

Continue Reading

FridayMay 24, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Participates in Three Investor Conferences During May 2024, Promoting CNM-Au8(R) Neuronal Health Therapy

Clene recently participated in the Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual Conference, and the Virtual A.G.P. Healthcare Conference CNM-Au8(R) is oral suspension developed to restore neuronal health and function by increasing energy production and utilization The therapy has been involved in clinical trials and compassionate use programs, accumulating over 600 years of exposure across various neurodegenerative conditions, with no safety concerns reported Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease, recently…

Continue Reading

FridayMay 24, 2024 9:00 am

PaxMedica Inc. (NASDAQ: PXMD) Seeking to Qualify for Neglected Tropical Disease Priority Review Voucher Program in Wake of Malawi Major Sleeping Sickness Crisis

PaxMedica has received an urgent plea from the Ministry of Health of Malawi for emergency access to IV suramin to prevent a potential humanitarian crisis due to dwindling supplies of essential drugs used to save lives in the region PaxMedica has previously concluded a Type B meeting with the FDA in preparation for the NDA submission, focusing on the use of PAX-101 in treating the rare and fatal trypanosomal infection, Trypanosoma brucei rhodesiense, transmitted by tsetse flies PaxMedica also aims to potentially qualify for a Priority Review Voucher under the Neglected Tropical Disease Priority Review Voucher Program, which could provide…

Continue Reading

ThursdayMay 23, 2024 12:00 pm

DealFlow Events Presents the 5th Annual Reg A & Crowdfunding Conference June 20, 2024

The 5th Annual Reg A & Crowdfunding Conference will take place at New York’s luxurious Westchester Country Club on June 20 The fifth annual conference will play host to investors, entrepreneurs and financiers as we to delve into the latest trends within the equity capital markets industry This year’s conference will feature a number of keynote presentations and speakers, including on topics such as the structuring and efficient marketing of Reg A+ and Crowdfunding deals Learn from (and network with) experts who raise capital with these powerful tools Equity capital markets have long been an attractive source of growth capital…

Continue Reading

ThursdayMay 23, 2024 11:15 am

4th Annual Psychedelic Therapeutics and Drug Development Conference Comes to Boston, MA

Researchers and leaders in academia, industry, the non-profit sector, and government organizations are invited to attend the 4th Annual Psychedelic Therapeutics and Drug Development Conference being held May 23-24, 2024, in Boston, MA. The conference focuses on discussing the hurdles as well as challenges in the research and development of psychedelics for various health conditions. Join the experts for this two-day conference that involves exploration, learning, discussion, and networking. Specific areas of discussion will include: Targets for novel drug development Toxicology studies and considerations The dosage debate and new evidence Second generation psychedelic drug design FDA regulatory guidance The speaker…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered